Archived Facts

Drug developer Dyax Corp. said Wednesday its second-quarter loss narrowed on a boost in revenue from the sale of its commercialization rights to the hemophilia drug Xyntha.

See the rest here:
Dyax 2Q loss narrows on sale of drug rights

Popular Posts:

Related Posts:

Leave a Reply